Tier 2 — strong

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C
Nature communications 2016 7; 12948

Bibliography

PubMed
PMID 27721479
PubMed Central
PMC5062546
Funding
ChromaDex sponsored the clinical study and supplied NR; additional research support is described in the paper.
Competing interests
Disclosures include ChromaDex employment, equity, research, advisory and consulting relationships, supplement-business interests and NAAD biomarker intellectual property.

Study snapshot

DesignHuman crossover pharmacokinetic study with supporting mouse experiments
ModelHuman participants
SampleOne-person pilot plus 12-person crossover PK study; separate mouse experiments
InterventionSingle oral NR doses of 100, 300 and 1000 mg
DurationAcute dose-response and time-course experiments
EndpointsBlood NAD+ metabolome; NAAD; dose and time response

What the study showed, in plain terms

Oral NR increased the blood NAD+ metabolome, and NAAD emerged as a sensitive marker of exposure. The paper includes both human and mouse experiments.

Key findings

The single-person pilot showed a blood NAD+ rise of up to 2.7-fold.

What this study can and cannot tell us

Small pharmacokinetic experiments establish biological availability, not clinical benefit or equivalence across all tissues.

Citation network

Articles citing this research paper

7 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified